Video

Dr. Grunwald on the Established and Potential Utility of Tisagenlecleucel in ALL

Michael R. Grunwald, MD, FACP, discusses the established and potential utility of tisagenlecleucel in patients with acute lymphoblastic leukemia.

Michael R. Grunwald, MD, FACP, a clinical assistant professor of medicine at the University of North Carolina, as well as a hematologist/oncologist at Levine Cancer Institute, Atrium Health, discusses the established and potential utility of tisagenlecleucel (Kymriah) in patients with acute lymphoblastic leukemia (ALL).

Having a CAR T-cell therapy available for patients with ALL has been exciting, according to Grunwald. However, the agent is only currently approved for use in younger patients with relapsed/refractory disease, and only those who are 25 years of age or younger can qualify for treatment. 

Further studies examining tisagenlecleucel and other agents in older patients with ALL will be important, as more options are needed for that population, Grunwald says. However, having tisagenlecleucel available for younger patients has been beneficial, as it has helped them achieve a durable remission following relapse, Grunwald concludes.

Related Videos
Kristen Spencer, DO
Mark Faries, MD
Lori A. Leslie, MD
Shyam A. Patel, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Marco Davila, MD, PhD
In this episode of OncChats: A Close Look at Clinical Trials in Oncology and Beyond, Dr Carvajal discusses the progress made in cancer clinical trials, with nearly 20,000 trials worldwide and over 80 FDA-approved cancer drugs since 2015, while also noting the challenges posed by the increasing complexity of therapies and trial protocols.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss ongoing research to watch in acute lymphoblastic leukemia.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss how to incorporate blinatumomab into clinical practice for ALL.